Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein

Virology

Volumn 454-455, Issue 1, 2014, Pages 139-144

  Bates, John T ^a   Keefer, Christopher J ^a,d   Slaughter, James C ^b   Kulp, Daniel W ^c   Schief, William R ^c   Crowe, James E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d MEHARRY MEDICAL COLLEGE   (United States)

Author keywords

Antibodies; Human; Monoclonal; Neutralizing; Palivizumab; Respiratory Syncytial Virus; Viral

Indexed keywords

HYBRID PROTEIN; MOTAVIZUMAB; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; COMPARATIVE STUDY; COMPLEX FORMATION; CORRELATIONAL STUDY; DRUG ACTIVITY; DRUG BINDING AND TRANSPORT; DRUG PROTEIN BINDING; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN RNA BINDING; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS IMMUNITY; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS RESISTANCE;

ANTIBODIES; HUMAN; MONOCLONAL; NEUTRALIZING; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS; VIRAL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; DRUG RESISTANCE, VIRAL; HUMANS; KINETICS; MUTATION; PROTEIN BINDING; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL FUSION PROTEINS;

EID: 84895091222     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.02.010     Document Type: Article

References (28)

1. Adams O., Bonzel L., Kovacevic A., Mayatepek E., Hoehn T., Vogel M. Palivizumab-resistant human respiratory syncytial virus infection in infancy. Clin Infect Dis 2010, 51:185-188.
2. Aiyegbo M.S., Sapparapu G., Spiller B.W., Eli I.M., Williams D.R., Kim R., Lee D.E., Liu T., Li S., Woods V.L., Nannemann D.P., Meiler J., Stewart P.L., Crowe J.E. Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. PLoS One 2013, 8:e61101.
3. Anon, 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531-537.
4. Bates J.T., Keefer C.J., Utley T.J., Correia B.E., Schief W.R., Crowe J.E. Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency. J Immunol 2013, 190:3732-3739.
5. Beeler J.A., van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 1989, 63:2941-2950.
6. Brock S.C., Heck J.M., McGraw P.A., Crowe J.E. The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence. J Virol 2005, 79:12528-12535.
7. Crowe J.E., Firestone C.Y., Crim R., Beeler J.A., Coelingh K.L., Barbas C.F., Burton D.R., Chanock R.M., Murphy B.R. Monoclonal antibody-resistant mutants selected with a respiratory syncytial virus-neutralizing human antibody fab fragment (Fab 19) define a unique epitope on the fusion (F) glycoprotein. Virology 1998, 252:373-375.
8. DeVincenzo J.P., Hall C.B., Kimberlin D.W., Sanchez P.J., Rodriguez W.J., Jantausch B.A., Corey L., Kahn J.S., Englund J.A., Suzich J.A., Palmer-Hill F.J., Branco L., Johnson S., Patel N.K., Piazza F.M. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 2004, 190:975-978.
9. Falsey A.R., Hennessey P.A., Formica M.A., Cox C., Walsh E.E. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005, 352:1749-1759.
10. Groothuis J.R., Nishida H. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab). Pediatr Int 2002, 44:235-241.
11. Henderson F.W., Collier A.M., Clyde W.A., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979, 300:530-534.
12. Kallewaard N.L., McKinney B.A., Gu Y., Chen A., Prasad B.V., Crowe J.E. Functional maturation of the human antibody response to rotavirus. J Immunol 2008, 180:3980-3989.
13. Leaver-Fay A., Tyka M., Lewis S.M., Lange O.F., Thompson J., Jacak R., Kaufman K., Renfrew P.D., Smith C.A., Sheffler W., Davis I.W., Cooper S., Treuille A., Mandell D.J., Richter F., Ban Y.E., Fleishman S.J., Corn J.E., Kim D.E., Lyskov S., Berrondo M., Mentzer S., Popovic Z., Havranek J.J., Karanicolas J., Das R., Meiler J., Kortemme T., Gray J.J., Kuhlman B., Baker D., Bradley P. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 2011, 487:545-574.
14. Liu C., Day N.D., Branigan P.J., Gutshall L.L., Sarisky R.T., Del Vecchio A.M. Relationship between the loss of neutralizing antibody binding and fusion activity of the F protein of human respiratory syncytial virus. Virol J 2007, 4:71.
15. McLellan J.S., Chen M., Kim A., Yang Y., Graham B.S., Kwong P.D. Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol 2010, 17:248-250.
16. McLellan J.S., Yang Y., Graham B.S., Kwong P.D. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011, 85:7788-7796.
17. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8:497-502.
18. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O'Brien K.L., Roca A., Wright P.F., Bruce N., Chandran A., Theodoratou E., Sutanto A., Sedyaningsih E.R., Ngama M., Munywoki P.K., Kartasasmita C., Simoes E.A., Rudan I., Weber M.W., Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
19. Steckbeck J.D., Orlov I., Chow A., Grieser H., Miller K., Bruno J., Robinson J.E., Montelaro R.C., Cole K.S. Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains. J Virol 2005, 79:12311-12320.
20. Top F.H., Connor E.M., Carlin D.A. Prophylaxis against respiratory syncytial virus in premature infants. IMpact-RSV Study Group. Lancet 2000, 355:1014.
21. VanCott T.C., Bethke F.R., Polonis V.R., Gorny M.K., Zolla-Pazner S., Redfield R.R., Birx D.L. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol 1994, 153:449-459.
22. Wu H., Pfarr D.S., Tang Y., An L.L., Patel N.K., Watkins J.D., Huse W.D., Kiener P.A., Young J.F. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005, 350:126-144.
23. Wu H., Pfarr D.S., Johnson S., Brewah Y.A., Woods R.M., Patel N.K., White W.I., Young J.F., Kiener P.A. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007, 368:652-665.
24. Zhao X., Chen F.P., Megaw A.G., Sullender W.M. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 2004, 190:1941-1946.
25. Zhao X., Chen F.P., Sullender W.M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 2004, 318:608-612.
26. Zhao X., Liu E., Chen F.P., Sullender W.M. In vitro and in vivo fitness of respiratory syncytial virus monoclonal antibody escape mutants. J Virol 2006, 80:11651-11657.
27. Zhu Q., McAuliffe J.M., Patel N.K., Palmer-Hill F.J., Yang C.F., Liang B., Su L., Zhu W., Wachter L., Wilson S., MacGill R.S., Krishnan S., McCarthy M.P., Losonsky G.A., Suzich J.A. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis 2011, 203:674-682.
28. Zhu Q., Patel N.K., McAuliffe J.M., Zhu W., Wachter L., McCarthy M.P., Suzich J.A. Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. J Infect Dis 2012, 205:635-638.